Compare LyondellBasell Industries NV (LYB) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
LyondellBasell Industries NV vs 10X Genomics Inc — how do they compare? LyondellBasell Industries NV trades at $61.36 (market cap $19.60B), while 10X Genomics Inc trades at $46.6 (market cap $5.48B). The key difference: LyondellBasell Industries NV is far larger — about 3.6× 10X Genomics Inc's market cap, and LyondellBasell Industries NV pays a 6.78% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.
| LYB | TXG | |
|---|---|---|
Market Cap | $19.60B | $5.48B |
Sector | Basic Materials | Health |
52-Week High | $82.38 | $45.80 |
52-Week Low | $42.28 | $11.34 |
Enterprise Value | $31.22B | $5.02B |
Dividend Yield | 6.78% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
LYB trades at $60.78, up 2.69% today, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals: revenue declined to $30.15B in 2025 with a net loss of $745M, yet valuation ratios like P/S of 0.64 appear attractive. Recent news highlights partnerships for sustainable packaging, while cash flow remains positive. Analysts are divided with a consensus price target of $73.11, suggesting 20% upside potential from current levels.
Outlook: LYB offers value appeal with low P/S and dividend yield, but faces profitability challenges and industry headwinds. Risks include volatile earnings and high debt. The stock is suitable for value investors tolerant of cyclical downturns, with catalysts from restructuring and sustainability initiatives.
TXG trades at $43.18, down 1.28% today, with a bullish technical signal and positive earnings momentum. The stock shows improving fundamentals with revenue growth to $642.82M in 2025 and narrowing losses, while maintaining a strong gross margin of 69.6%. Recent acquisitions and partnerships with Cleveland Clinic demonstrate strategic expansion in genomic diagnostics.
The outlook remains cautiously optimistic with analyst consensus at Buy (45%) and price target of $39.14. Key risks include continued negative profitability metrics and high valuation multiples, while catalysts include upcoming Q2 2026 earnings and platform adoption growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About LyondellBasell Industries NV
LyondellBasell Industries NV is a petrochemical producer with operations in the U.S. and Europe. It operates in six segments: Olefins and Polyolefins-Americas (O&P-Americas), Olefins and Polyolefins-Europe, Asia, International (O&P-EAI), Intermediates and Derivatives (I&D), Advanced Polymer Solutions (APS), Refining and Technology. The company is a major producer of polyethylene, the world's largest producer of polypropylene, and the second- largest producer of propylene oxide. Its chemicals are used in various consumer and industrial end products. Substantially, all of the company's revenue is derived from product sales.
Read more on LYB →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
